RESEARCH AND DEVELOPMENT
Developing a safe, disease-modifying treatment for peanut allergy
June 4, 2019
Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma
June 4, 2019, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for pe...